Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Morning Bell 1 June

Sophia Mavridis
June 1, 2022

Morning Bell 31 May

Paulina Peters
May 31, 2022

Morning Bell 30 May

Sophia Mavridis
May 30, 2022

Weekly Wrap 27 May

Sophia Mavridis
May 27, 2022

Morning Bell 25 May

Paulina Peters
May 26, 2022

Morning Bell 25 May

Paulina Peters
May 25, 2022

Morning Bell 24 May

Sophia Mavridis
May 24, 2022

Morning Bell 23 May

Sophia Mavridis
May 23, 2022

Weekly Wrap 20 May

Sophia Mavridis
May 20, 2022

Morning Bell 19 May

Paulina Peters
May 19, 2022

Morning Bell 18 May

Sophia Mavridis
May 18, 2022

Morning Bell 17 May

Sophia Mavridis
May 17, 2022